🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Recurrent Non-small Cell Lung Cancer

RGL-270 + ICI in Advanced NSCLC NCT07652125NA1 site📍 Guangzhou Guangdong Association of Clinical Trials · Tests: RGL-270 in Combination with PD-1/PD-L1 Inhibitors, Physician's Choice SOC A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks NCT07469709n/a1 site📍 Candiolo Fondazione del Piemonte per l'Oncologia Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer NCT07057102n/a1 site📍 Beijing Cancer Institute and Hospital, Chinese Academy of Medical S… Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC NCT05669846Phase 21 site📍 Pittsburgh Diwakar Davar · Tests: Healthy Donor Fecal Microbiota Transplant (hdFMT), Pembrolizumab Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) NCT07393555Phase 241 sites📍 Berkeley📍 Palo Alto📍 Sacramento SWOG Cancer Research Network · Tests: Biospecimen Collection, Computed Tomography, Ivonescimab, Magnetic Resonance Imaging, Sacituzumab Govitecan Stereotactic Radiation for Growing/Changing Brain Metastases With Same-Day Radiation Planning and Treatment With Margin Reduction NCT07132190Phase 21 site📍 Boston Ayal A. Aizer, MD · Tests: Linear accelerator-based stereotactic radiation for brain metastases using 0mm or 1mm PTV An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer. NCT07357597Phase 441 sites📍 Tucson📍 Hot Springs📍 Little Rock AstraZeneca · Tests: Dexamethasone mouthwash, Datopotamab Deruxtecan (Dato-DXd) Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. NCT07279935Phase 432 sites📍 Beijing📍 Beijing📍 Beijing AstraZeneca · Tests: Osimertinib+cisplatin or carboplatin + pemetrexed Edit A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069Phase 139 sites📍 Duarte📍 La Jolla📍 Los Angeles Eli Lilly and Company · Tests: LY4052031, Pembrolizumab PBF-1129 and Nivolumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer NCT05234307Phase 11 site📍 Columbus Dwight Owen · Tests: Adenosine A2B Receptor Antagonist PBF-1129, Biospecimen Collection, Nivolumab Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations NCT05701787n/a2 sites📍 Shanghai📍 Shanghai Shanghai Chest Hospital Efficacy and Safety of Vorolanib Monotherapy As Third-line or Later Treatment for Advanced Non-small Cell Lung Cancer Patients: a Single-arm, Prospective, Open-label Phase II Clinical Study NCT06728852Phase 21 site📍 Guangzhou Li-kun Chen · Tests: Administration of Vorolanib Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases NCT07130786Phase 21 site📍 Boston Ayal A. Aizer, MD · Tests: Levetiracetam (Keppra) A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression NCT06682793Phase 1, Phase 210 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B395, xT CDx with HLA-LOH assay Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites📍 Phoenix📍 Jacksonville📍 Rochester Mayo Clinic · Tests: Biospecimen Collection, Tissue Collection Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC NCT04467723Phase 1, Phase 22 sites📍 Fairway📍 Kansas City University of Kansas Medical Center · Tests: Atezolizumab Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program NCT06265285Phase 21 site📍 Jacksonville Mayo Clinic · Tests: Home Health Encounter, Nivolumab, Patient Monitoring, Questionnaire Administration Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic NCT07807345Phase 16 sites📍 Orlando📍 Boston📍 Oklahoma City Sutro Biopharma, Inc. · Tests: STRO-006, Pembrolizumab Evaluate the Safety, Tolerability, Biodistribution Characteristics and Preliminary Efficacy of BioTTT001 NCT07264569Phase 1, Phase 21 site📍 Zhengzhou Henan Cancer Hospital · Tests: BioTTT001 injection Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment NCT05363280Phase 27 sites📍 Birmingham📍 Weston📍 Chicago Advenchen Pharmaceuticals, LLC. · Tests: AL8326 40 mg, AL8326 60 mg, AL8326 80 mg--stopped Clinical Study on the Prevention of Driver Gene Negative Ib-IIIb Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors NCT05834413NA1 site📍 Shanghai Shanghai University of Traditional Chinese Medicine · Tests: chemotherapy plus TCM 1&ICIs plusTCM2, chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) NCT06031688Phase 2278 sites📍 Daphne📍 Fairhope📍 Mobile SWOG Cancer Research Network · Tests: Biospecimen Collection, Computed Tomography, Lymphoscintigraphy, Magnetic Resonance Imaging, Ramucirumab Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer NCT04614103Phase 271 sites📍 Gilbert📍 Miami📍 Tampa Iovance Biotherapeutics, Inc. · Tests: LN-145, LN-145 Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer NCT06463665Phase 215 sites📍 Bullhead City📍 Clermont📍 Coral Springs Genelux Corporation · Tests: Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or … First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer NCT06799065Phase 1, Phase 211 sites📍 Aurora📍 Sarasota📍 Detroit Accent Therapeutics · Tests: ATX-295, ATX-295 and bevacizumab (or biosimilar) A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer NCT05361174Phase 1, Phase 211 sites📍 Los Angeles📍 Miami📍 Orlando Iovance Biotherapeutics, Inc. · Tests: IOV-4001 A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors NCT05150691Phase 1, Phase 2102 sites📍 Cerritos📍 Los Angeles📍 San Diego DualityBio Inc. · Tests: DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) NCT05642572Phase 2454 sites📍 Daphne📍 Fairhope📍 Mobile SWOG Cancer Research Network · Tests: Biospecimen Collection, Capmatinib, Computed Tomography, Magnetic Resonance Imaging, Osimertinib A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression NCT06051695Phase 1, Phase 212 sites📍 Gilbert📍 La Jolla📍 Los Angeles A2 Biotherapeutics Inc. · Tests: A2B694, A2B543, xT CDx with HLA-LOH Assay First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer NCT07355205Phase 1, Phase 21 site📍 St Louis Washington University School of Medicine · Tests: Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy